@article{2151178,
  abstract     = {Background and objectives: Antibody persistence and immune memory against hepatitis A (HAV) in adults in a low endemicity country, 15 y after immunisation with two doses of HAV vaccine has been demonstrated. This communication provides additional information on antibody persistence up to Year 17 from two of the longest follow-up studies [NCT00289757/NCT00291876]. 
Methods: In two double-blind primary studies, healthy adults aged 17-40 y and 21-40 y, respectively received two doses of the HAV vaccine following a 0,6 mo or 0,12 mo schedule. Anti-HAV antibody concentrations were measured using an enzyme-linked immunoassay (cut-off: 15mIU/ml) at Year 16 and Year 17. Subjects who became seronegative (anti-HAV {\textlangle} 15mIU/ml) since previous reporting were offered a challenge dose, with anti-HAV antibody concentration measurements at Day 14 and Day 30 thereafter. 
Results: At Year 17, 100\% and 96.7\% of subjects remained seropositive for anti-HAV antibodies following the 0, 6 mo and 0, 12 mo regimens, respectively (GMCs: 278mIU/ml and 369mIU/ml). One subject who became seronegative at Year 16 received a HAV challenge dose within the next 12 mo and mounted an anamnestic response. The challenge dose was well-tolerated. 
Conclusions: Both HAV immunisation regimens (0,6 mo and 0,12 mo) induced persistence of vaccine-induced antibodies against HAV for at least 17 y after primary vaccination.},
  author       = {Van Herck, Koen and Crasta, Priya Diana and Messier, Marc and Hardt, Karin and Van Damme, Pierre},
  issn         = {2164-5515},
  journal      = {HUMAN VACCINES \& IMMUNOTHERAPEUTICS},
  language     = {eng},
  number       = {3},
  pages        = {5},
  title        = {Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccine},
  url          = {http://dx.doi.org/10.4161/hv.8.3.18617},
  volume       = {8},
  year         = {2012},
}

Altmetric

View in Altmetric

Web of Science

Times cited: